Kornimate/medical-research-clean huggingface dataset:
feasibility and effectiveness of nutritional telemonitoring in community-dwelling elderly.

Conditions: Undernutrition; Aging

Summary: an optimal nutritional status is essential for healthy ageing. telemonitoring might contribute to maintaining or improving nutritional status in elderly people.the objectives of this effect study are to test the feasibility and effectiveness of telemonitoring of nutritional parameters in community-dwelling older adults.


Eligibility criteria:
inclusion criteria: having a care referral for at least one of the following types of care: * domestic care * personal care * nursing care * individual or group support * living in a sheltered home or service flat exclusion criteria: * severe cognitive impairment (mini mental state examination (mmse) \< 20) * receiving terminal care * not having a television at home * clients with a visual impairment (not able to watch the television screen) * clients with a physical impairment in such a way, that they are not able to use the telemonitoring system * clients with nursing home care

Keywords: ehealth older adults undernutrition
cbsm intervention via mhealth to ameliorate hiv-related fatigue

Conditions: HIV; Stress Disorder; Human Immunodeficiency Virus; Fatigue

Summary: the purpose of this study is to create a smartphone, tablet and web-based application to help people deal with stress. stress often increases fatigue in people with hiv infection, so successfully dealing with stress could help reduce hiv-related fatigue. the study is being done at one site, the medical university of south carolina. approximately 30 people will take part in this portion of the study.

for this study we will develop a fatigue symptom self-management cognitive behavioral stress management (cbsm) program that will be delivered via mhealth through smartphones and tablets (optimized for each). all cbsm content will be integrated into the application, but tailoring of information delivery will be derived through algorithm-driven feedback based on user input as they respond to integrated assessment and symptom monitoring questions. as a result, users of the cbsm-self management intervention (cbsm-smi) will receive personalized, relevant intervention content, when they need it, where they need it. this novel mode of cbsm delivery has not yet been provided via an mhealth format to hiv-infected individuals, despite its obvious advantages insofar as cost and reach are concerned.

Eligibility criteria:
inclusion criteria: * hiv positive * reads and understands english * scores greater than 5 on the hiv-related fatigue scale * mentally competent to give informed consent exclusion criteria: * co-morbid conditions marked by fatigue (e.g., renal disease, cancer, multiple sclerosis) * pregnant women and women who are less than 1 year postpartum * active psychosis or dementia * suicidal ideation with clear intent * current substance dependence

Keywords: self-management mhealth
cholestanol in humans

Conditions: Cerebrotendinous Xanthomatosis

Summary: the treatment of cerebrotendinous xanthomatosis an in born error of bile acid synthesis with chenodeoxycholic acid. patients with this disease over produce cholestanol and bile acid precursors because of the block in synthesis. replacement with chenodeoxycholic acid shut down abnormal pathway and reduces elevated level of cholestanol and improves the clinical syndrome.

cerebrotendinous xanthomatosis is a recessively inherited in born of bile acid synthesis due to a mutation in sterol 27-hydroxylase (cyp27a1). patients with this disease suffer from xanthomas located in the brain and tendon, accelerated atherosclerosis progression neurologic disease and cataracts. plasma cholesterol levels are normal but cholestanol and c-27 bile alcohol that precursor of bile acid synthesis accumulate and are believe are responsible for the atherosclerosis, xanthomas and neurologic disease. analysis of the bile reveal a severe sufficiency of the primary bile acid chenodeoxycholic acid that can not be produce because of the inherited defect. however, replacement of chenodeoxycholic acid in the enterohepatic pool inhibit abnormal bile acid synthesis and reduces the elevated level of cholestanol and c-27 bile alcohol this therapy halt the neurologic disease and prevents symptomatic atherosclerosis developing.

Eligibility criteria:
inclusion criteria: patients with clinical and biochemical findings of cerebrotendinous xanthomatosis. elevated levels of serum cholestanol and bile acid precursors. exclusion criteria:

Keywords: bile acid synthesis chenodeoxycholic acid sterol 27-hydroxylase
role of skin tests for the diagnosis of immediate hypersensitivity reactions due to iodinated contrast media

Conditions: Hypersensitivity

Summary: the purpose of this trial is to study the diagnostic role of skin test in immediate reactions to iodinated radiocontrast media.


Eligibility criteria:
inclusion criteria: 1. patients with history of immediate hypersensitivity reactions to iodinated contrast media 2. 15-70 years of age exclusion criteria: 1. on antihistamine/ cannot discontinue antihistamine before the test 2. having asthma exacerbation 3. being pregnant 4. suffering from severe systemic disease/ in bad health

Keywords: contrast media skin test skin test hypersensitivity contrast media
pa21 phase ii clinical study in hemodialysis patients with hyperphosphatemia

Conditions: Chronic Kidney Disease Requiring Hemodialysis

Summary: to investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.


Eligibility criteria:
inclusion criteria: * patients age 20 or older, regardless of gender. * receiving stable maintenance hemodialysis 3 times a week. * patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start. exclusion criteria: * patients having history of a pronounced brain / cardiovascular disorder. * patients having severe gastrointestinal disorders. * patients having severe hepatic disorders.

Keywords: hemodialysis hyperphosphatemia
perioperative melatonin in lumbar laminectomy

Conditions: Pain and Anxiety in Patients Undergoing Surgery for Lumbar Laminectomy.

Summary: patients undergoing lumbar laminectomy surgery will receive either 5 or 10 mg melatonin or placebo once the evening before surgery and again 90 minutes before surgery. pain and anxiety will be assessed over the 24 hour period following surgery.


Eligibility criteria:
inclusion criteria: * age 18 to 65 years old * asa status 1-3 * having lumbar laminectomy 2 to 3 levels with or without fusion exclusion criteria: * receiving emergent procedure * surgery for neoplastic spine lesion * allergy to melatonin or its non-medicinal ingredients * allergy or contraindication * bmi over 35 or or less than 20 kg/m2 * pregnancy or breastfeeding * failure to provide informed consent

Keywords: lumbar laminectomy, melatonin, perioperative, pain, anxiety, analgesia, vas score
pharmacokinetics and safety of single-dose telbivudine in children and adolescents with chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: this is a phase i, open-label, single-dose study to evaluate the pharmacokinetics and safety of ldt600 in pediatric and adolescent patients with chronic hepatitis b infection.


Eligibility criteria:
inclusion criteria: * children and adolescents patients * hbsag seropositive exclusion criteria: * decompensated liver disease (child-turcotte-pugh (ctp) score≥7, class b and c) * prior anti-hbv therapy within 30 days of study drug dosing. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: chronic hepatitis b, telbivudine, pharmacokinetics, safety, tolerability, pediatric
postural drainage and pep technique in community acquired pneumonia

Conditions: Community-acquired Pneumonia

Summary: community-acquired pneumonia is acquired outside the hospital. postural drainage is the positioning of a patient with an involved lung segment such that gravity has a maximal effect of facilitating the drainage of broncho-pulmonary secretions from the tracheobronchial tree. it is based on the concept of gravity-assisted mobilization of secretions and transports it for removal. the objective of the study to find the effect of postural drainage and positive expiratory pressure techniques (pep) to improve the air way clearance and breathing in pneumonia patients. this study will be a rct and will be conducted in services hospital. the study will be completed within the duration of six month. consecutive sampling study technique will be used to collect the data. the sample size of 46 patients will be taken. patients will be divided into two groups. (group a will be treated with postural drainage and group b will be treated with positive expiratory pressure technique). outcome measure will be taken on pulse oximeter, incentive spirometer and chest x- ray. a regular follow up visits to department and a final assessment was made at the end of four week. data will be analyzed using spss software version 25. after assessing normality of data by shapiro- wilk test, it will be decided either parametric or non-parametric test will be use within a group or between two groups.


Eligibility criteria:
inclusion criteria: * diagnosed with community acquired pneumonia. * clinically stable patients. * both genders * age 30 to 70 years exclusion criteria: * presence of any genetic disorders (cystic fibrosis). * recent spinal / chest surgery * cardiac issues * fractures of vertebra caused by osteoporosis.

Keywords: pneumonia, postural drainage positive expiratory pressure
reminiscences and emotions : reminiscence triggered by virtual reality for older adults with mood disorders

Conditions: Alzheimer Disease; Mood Disorders; Virtual Reality

Summary: presentation \& pre-screening of the control group / reminiscence group patient/resident pre-screening team meeting for the study explanation and proposal of the study to patients and their families signature of resident/patient and family consents audit of inclusion and non-inclusion criteria inclusion medical advice for vr clinical interview with the family or legal guardian for an accurate life history + an anamnesis interview (psychologist or doctor) with the patient or resident. creation of video contents creation of personalized video contents clinical scales review evaluation of the number of psychotropic molecules prescribed (coordinating doctor, general practitioner, geriatrician) * pre-test phase with the patient for the use of the vr headset * randomisation * session procedure as previously mentioned, the virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. the sessions will be hold over a period of time of 6 weeks. each subject of the reminiscence group will have two personalised virtual surroundings (after data being collected from team and/or families). the virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation. the subjects of the control group will be exposed to two generic virtual settings (beach, mountain etc.) with a different virtual environment every 3 weeks. during the session, note will be taken on the subject's speech. the session will also be filmed and/or recorded with a prior signed agreement by the patient or his representative. - last session (s6) review of clinical scales (re-testing) re-evaluation of drug prescriptions


Eligibility criteria:
inclusion criteria: * male or female aged 65 or older * accompanied in day care or in the geriatric structure of the chu of nice (ehpad-usld) * mild to moderate cognitive impairment * diagnostic criteria for alzheimer's disease, nincds-adrda probably, * positive score on at least one of the following rating scales : * npi-es depression/dysphoria and anxiety items + gds 15 patients * ia caregiver = 2 on one of 2 dimensions + ia patient = 2 on one of 2 dimensions exclusion criteria: * diagnosed psychiatric pathology * disabling sensory disorders such as dmla * significant hearing loss * subjects with risk of photosensitive epilepsy or dizziness. subjects with lewy body dementia
efavirenz and lamivudine/zidovudine for treatment-naive hiv infected people in wenxi county, shanxi province, china

Conditions: HIV Infections

Summary: the purpose of this study is to determine the safety, effectiveness, and tolerability of the anti-hiv drugs efavirenz and lamivudine/zidovudine given to treatment-naive hiv infected people in wenxi county, shanxi province, china.

hiv infection in china has reached epidemic proportions, especially in poor rural communities. among the infected are former commercial plasma donors who became infected through contaminated blood collection equipment. this study will evaluate the safety, efficacy, and tolerability of an antiretroviral (arv) regimen given to treatment-naive hiv infected adults. participants will be recruited in wenxi county, shanxi province. this study will last 1 year. at study entry, all study participants will be given an arv regimen consisting of lamivudine/zidovudine twice daily and efavirenz once daily. there will be 11 study visits; a physical exam, blood collection, and vital signs measurement will occur at all study visits. participants will also receive safe sex and adherence counseling at all visits. participants will be asked to complete an adherence questionnaire and will have their pills counted at most visits.

Eligibility criteria:
inclusion criteria: * hiv infected * antiretroviral naive * cd4 count of less than 350 cells/mm3 within 30 days of study entry * willing to use acceptable forms of contraception * willing to stay in the study area for the duration of the study * willing to not consume traditional chinese medicines for the duration of the study * willing to adhere to the follow-up study schedule exclusion criteria: * presence of an acute serious medical illness within 14 days prior to study entry. participants with recently diagnosed opportunistic infections (except tuberculosis \[tb\]) and are stable on therapy for more than 30 days are eligible. * current pancreatitis * require certain medications * pregnant or breastfeeding

Keywords: treatment naive
institut paoli calmettes prostate cancer database

Conditions: Prostatic Neoplasms

Summary: database of institut paoli-calmettes patients diagnosed with prostate cancer


Eligibility criteria:
inclusion criteria: * prostatic cancer exclusion criteria: * non applicable
mucopolysaccharidosis i (mps i) registry

Conditions: Mucopolysaccharidosis I (MPS I)

Summary: the mucopolysaccharidosis i (mps i) registry is an ongoing, observational database that tracks the outcomes of patients with mps i. the data collected by the mps i registry will provide information to better characterize the natural history and progression of mps i as well as the clinical responses of patients receiving enzyme replacement therapy, such as aldurazyme (recombinant human alpha-l-iduronidase), or other treatment modalities. the objectives of the registry are: * to evaluate the long-term effectiveness and safety of aldurazyme® (laronidase) * to characterize and describe the mps i population as a whole, including the variability, progression, and natural history of mps i * to help the mps i medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care

the mps i registry is an international program; in addition to the central contact information provided under the "location" heading, patients may contact: * in asia-pacific - vivian liu, +65-6431-2548, vivian.liu@genzyme.com * in europe - +31-35-699-1232, europe@mpsiregistry.com * in latin america - +617-591-5500, help@mpsiregistry.com * in north america - +617-591-5500, help@mpsiregistry.com

Eligibility criteria:
inclusion criteria: * all patients with a confirmed diagnosis of mps i are eligible for inclusion. confirmed diagnosis is defined as: a. documented biochemical evidence of a deficiency in alpha (a)-l-iduronidase enzyme activity and/or b. mutation(s) in the gene coding for a-l-iduronidase, or measurable clinical signs and symptoms of mps i * for all patients there should be a completed patient authorization form exclusion criteria: * no exclusion criteria for participation in the mps i registry. note: registry participation does not exclude participation in other clinical studies.

Keywords: hurler's syndrome hurler-scheie syndrome scheie syndrome
randomized clinical trial of supplementing brief psychotherapy with a mobile app

Conditions: Suicidal Ideation; Suicide; Suicide Attempt

Summary: the aim of this study is to determine whether learning three skills for managing negative emotions and receiving reminders via smartphone to practice these skills reduces how often and how intensely one experiences emotional distress and suicidal thoughts.

this study is a companion project to nct05848089. the present study is a two-arm parallel design rct to test the efficacy of using ecological momentary intervention (emi) to deliver therapeutic content based on the unified protocol for the transdiagnostic treatment of emotional disorders (up) - an evidence-based transdiagnostic cognitive behavioral therapy (cbt) that focuses on delivering adaptive skills for managing strong emotions. participants in this study will be 50 adult psychiatric inpatients with recent suicidal thoughts or behaviors (stbs). participants will be randomized to receive either the control condition, which consists of treatment as usual (tau; n = 25) and 4x/daily daily ecological momentary assessment (ema) of emotions and stbs, or the experimental condition, consisting of tau, 4x/daily ema, 3 brief sessions to deliver cbt skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors, all drawn from the up), and emi to prompt guided skills practice (n = 25). control participants will receive tau and be prompted to complete 4x/day ema of emotions and stbs for the duration of their hospital stay and the 28-day post-discharge period. participants randomized to the experimental conditions will receive tau plus three brief treatment sessions delivering core up skills content (during inpatient stays) that may be offered after discharge via either phone or telehealth. those in the experimental condition will also receive training to use the emi (which prompts guided skills practice), followed by smartphone-based for the 28-day post-discharge period.

Eligibility criteria:
inclusion criteria: * adult status (18+ years), * a recent suicide attempt or any report of current suicidal ideation, * the ability to speak and write english fluently, ownership of and consistent access to an internet-capable smartphone (e.g., an iphone or android phone), and exclusion criteria: - the presence of any factor that impairs an individual\&#39;s ability to provide informed consent and comprehend and effectively participate in the study including: an inability to speak or write english fluently, the presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior.

Keywords: suicide attempt suicide suicidal ideation unified protocol ecological momentary intervention mhealth
antibiotic therapy practices for ventilator-associated pneumonia (petunia)

Conditions: Ventilator Associated Pneumonia

Summary: the french society of intensive care conducts a comprehensive assessment of current antibiotic therapy practices in critically ill patients suspected of ventilator-associated pneumonia (vap).

this prospective observational multicenter study will be conducted in intensive care units (icu) across france and french-speaking regions. the primary objective of this study is to delineate the characteristics of antibiotic treatments administered for a first episode of suspected vap. secondary objectives include describing the outcomes of enrolled patients, assessing adherence to european guidelines regarding empirical antibiotic treatment, and identifying factors associated with mortality in patients with microbiologically confirmed vap.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * admission to the icu * intubation and duration of invasive mechanical ventilation \> 48 hours * initiation of new antibiotic therapy to treat a first suspicion of ventilator-associated pneumonia (vap) exclusion criteria: * presence of a decision to limit active therapeutic measures at the time of initiating antibiotic therapy * organ donor * prior inclusion in the study during a previous stay in the intensive care unit (a patient cannot be included multiple times) * participation in an interventional study focusing on the management of vap and directly impacting antibiotic therapy practices * patient and/or family opposition to participation * lack of affiliation with a social security system

Keywords: antibiotic intensive care guidelines outcome
a chronic obstructive pulmonary disease (copd) trial investigating roflumilast on safety and effectiveness in china, hong kong and singapore:

Conditions: COPD

Summary: the aim of this trial is to determine the efficacy, safety and tolerability of 500 µg roflumilast tablets once daily in patients with copd in china, hong kong, and singapore.


Eligibility criteria:
main inclusion criteria: * willingness to sign a written informed consent * chronic obstructive pulmonary disease (copd) according to global initiative for chronic obstructive lung disease (gold) guidelines 2009 * chinese or malay or indian ethnicity * history of chronic obstructive pulmonary disease symptoms for at least 12 months prior to baseline visit v0 * forced expiratory volume in the first second/ forced vital capacity (fev1/fvc) ratio (post-bronchodilator) \< 70% * forced expiratory volume in the first second (fev1) (post-bronchodilator) \< 50 % of predicted * former smoker (defined as: smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years main exclusion criteria: * moderate or severe copd exacerbation and/or copd exacerbations treated with antibiotics not stopped at v0 * lower respiratory tract infection not resolved 4 weeks prior to the baseline visit v0 * history of asthma diagnosis in patients \< 40 years of age or relevant lung disease other than copd * current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the baseline visit v0 * known alpha-1-antitrypsin deficiency

Keywords: copd roflumilast fev1 china